News Summary

San Diego startup Gallant has announced $18 million in funding to develop the first FDA-approved ready-to-use stem cell therapy for veterinary medicine. Gallant aims to address Feline Chronic Gingivostomatitis (FCGS) and potentially other conditions in pets. The company’s approach is unique, using ready-to-use cells from donor animals, unlike traditional methods that require harvesting cells from the patient or matching donors. The funding round was led by Digitalis Ventures, with NovaQuest Capital Management also participating. Gallant was founded by Aaron Hirschhorn, who passed away in 2021, and is now led by Linda Black.